Medical Condition News

RSS

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

Cameron Health initiates clinical trial of minimally invasive S-ICD System for patients at risk of SCA

Cameron Health, Inc. today announced the commencement of the company's pivotal clinical trial to gain U.S. approval of its Subcutaneous Implantable Defibrillator (S-ICD®) System. The minimally invasive S-ICD System is prescribed for use in patients at risk of Sudden Cardiac Arrest (SCA). The S-ICD System is unique in that the implantation of the system is entirely subcutaneous; no leads are in or on the heart.

19 Mar 2010

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

The University of Pennsylvania and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.

19 Mar 2010

Call for European Cystic Fibrosis healthcare gap to be closed

A healthcare gap amounting to a ‘death sentence’ for Cystic Fibrosis (CF) children born in Eastern Europe must be closed say researchers from the EuroCareCF Coordination Action for Cystic Fibrosis.

18 Mar 2010

Stiff skin syndrome cause found

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about scleroderma, a condition affecting about one in 5,000 people that leads to hardening of the skin as well as other debilitating and often life-threatening problems. The findings, which appear this week in Science Translational Medicine, open doors to testing new treatments.

18 Mar 2010

Broad application of bipolar diagnosis in children may do more harm than good

Troubled children diagnosed with bipolar disorder may fare better with a different diagnosis, according to researchers at The Hastings Center.

18 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

Southern California’s Sexual Recovery Institute introduces additional Intensive Outpatient Programs

Southern California’s Sexual Recovery Institute (SRI), the leading outpatient treatment center for sex addiction, has announced additional Intensive Outpatient Programs (IOP). The expansion is a result of increased awareness of sex addiction issues as the mainstream media begins to shed light on high profile scandals and subsequent treatment methods.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

New program designed to improve law enforcement responses to the mentally ill

The Department of Justice's Office of Justice Programs today announced the release of a publication designed to improve law enforcement responses to people with mental illnesses. The report shows there is no one-size-fits-all approach, but a growing number of communities are implementing Specialized Policing Responses that are designed to improve outcomes and encounters involving people with mental illnesses.

18 Mar 2010

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish, offers hope for thousands of patients at risk of developing an inherited form of bowel cancer, a new study shows.

18 Mar 2010

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

The Canadian Cancer Society, BC and Yukon, is stepping up the fight by announcing today the launch of an inaugural daffodil pin - a badge of courage - as part of its annual Daffodil month campaign when canvassers go door-to-door.

18 Mar 2010

Evaluating functional significance of blockages in cardiac blood vessels with formulas from fluid mechanics

Improved care for cardiac patients and people with coronary artery disease is the goal of a new pilot study being led by engineering and medical researchers at the University of Cincinnati (UC) and the Cincinnati Department of Veterans Affairs (VA) Medical Center.

18 Mar 2010

Researchers find some similarities between SPN and PET

Solid-pseudopapillary neoplasm (SPN) of the pancreas is relatively rare. There are some similarities between SPN and pancreatic endocrine tumor (PET), especially the non-functioning ones, in clinical and pathological manifestations.

18 Mar 2010

Study finds the cost of cancer care is skyrocketing

USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.

18 Mar 2010

New book exposes the ignored causes of three major life-threatening and chronic diseases

In his newest book, "Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis" (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and often ignored causes of three major life-threatening and chronic diseases: cancer, cardiovascular disease and multiple sclerosis.

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

Medical Condition News

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Cameron Health initiates clinical trial of minimally invasive S-ICD System for patients at risk of SCA

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

Call for European Cystic Fibrosis healthcare gap to be closed

Stiff skin syndrome cause found

Broad application of bipolar diagnosis in children may do more harm than good

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Southern California’s Sexual Recovery Institute introduces additional Intensive Outpatient Programs

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

New program designed to improve law enforcement responses to the mentally ill

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

Evaluating functional significance of blockages in cardiac blood vessels with formulas from fluid mechanics

Researchers find some similarities between SPN and PET

Study finds the cost of cancer care is skyrocketing

New book exposes the ignored causes of three major life-threatening and chronic diseases

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News